# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# **SCHEDULE 13G**

Under the Securities Exchange Act of 1934 (Amendment No. )\*

# ATARA BIOTHERAPEUTICS, INC.

(Name of Issuer)

Common Stock, \$0.0001 par value per share (Title of Class of Securities)

> 046513107 (CUSIP Number)

October 16, 2014 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

□ Rule 13d-1(b)

 $\boxtimes$  Rule 13d-1(c)

 $\Box$  Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

## CUSIP No. 046513107

	. 04031310			
1)	Names	of reporting persons.		
		EN INC.		
2)	Check the appropriate box if a member of a group (see instructions) (a) $\Box$ (b) $\Box$			
	(a) 🗆			
3)	SEC us	se only		
4)	Citizen	ship or place of organization		
	Delaw			
	Delaw	5. Sole voting power		
		5. Sole voting power		
		615,384		
	ber of tres	6. Shared voting power		
	icially			
	ed by	853,117(1)		
	ch rting	7. Sole dispositive power		
per	son	615,384		
wi	th:	8. Shared dispositive power		
		853,117(1)		
9)	Aggreg	ate amount beneficially owned by each reporting person		
	1,468,501			
10)		if the aggregate amount in Row (9) excludes certain shares (see instructions)		
10)	Check	in the aggregate amount in Now (9) excludes certain shares (see instructions)		
11)	Percent of class represented by amount in Item 9			
-				
	6.0% (2)			
12)	Type of reporting person (see instructions)			
	СО			

(1) Represents shares of Issuer common stock held directly by Amgen Investments Ltd., an indirect wholly owned subsidiary of Amgen Inc.

(2) Based on 24,360,247 shares of Issuer common stock outstanding as of February 18, 2015, as reported in the Issuer's Annual Report on Form 10-K filed on February 26, 2015, as amended on March 6, 2015.

1)     Names of reporting persons.       AMGEN INVESTMENTS LTD.       2)     Check the appropriate box if a member of a group (see instructions)       (a)     □       (b)     □       3)     SEC use only       4)     Citizenship or place of organization				
2)     Check the appropriate box if a member of a group (see instructions)       (a)     □     (b)       3)     SEC use only				
(a) □     (b) □       3)     SEC use only				
4) Citizenship or place of organization				
, Frank Galaxie				
Bermuda				
5. Sole voting power				
Number of 0				
shares 6. Shared voting power				
beneficially owned by 853,117				
each 7. Sole dispositive power				
person 0 with:				
8. Shared dispositive power				
853,117				
9) Aggregate amount beneficially owned by each reporting person				
853,117				
10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) $\Box$	Check if the aggregate amount in Row (9) excludes certain shares (see instructions)			
11) Percent of class represented by amount in Item 9				
3.5% (1)	3.5% (1)			
12) Type of reporting person (see instructions)	Type of reporting person (see instructions)			
00				

 Based on 24,360,247 shares of Issuer common stock outstanding as of February 18, 2015, as reported in the Issuer's Annual Report on Form 10-K filed on February 26, 2015, as amended on March 6, 2015.

## ITEM 1.

(A) NAME OF ISSUER:

Atara Biotherapeutics, Inc.

# (B) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICE:

701 Gateway Blvd., Suite 200, South San Francisco, California 94080

## ITEM 2.

(A) NAME OF PERSONS FILING:

Amgen Inc., a Delaware corporation Amgen Investments Ltd., a Bermuda corporation

#### (B) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR IF NONE, RESIDENCE:

Amgen Inc: One Amgen Center Drive, Thousand Oaks, California 91320-1799 Amgen Investments Ltd.: Canon's Court, 22 Victoria Street, Hamilton, HM 12, Bermuda

(C) CITIZENSHIP:

Amgen Inc.: Delaware, U.S.A. Amgen Investments Ltd.: Bermuda

(D) TITLE OF CLASS OF SECURITIES:

Common Stock, \$0.0001 par value

(E) CUSIP NUMBER: 046513107

ITEM 3. STATEMENT FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B) OR (C) Not applicable.

ITEM 4. OWNERSHIP.

(a), (b) and (c)—The information contained on the cover pages to this Schedule 13G are incorporated herein by reference.

ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

Not applicable.

ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON Not applicable.

# ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON

Not applicable.

# ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

Not applicable.

## ITEM 9. NOTICE OF DISSOLUTION OF GROUP

Not applicable.

# ITEM 10. CERTIFICATION.

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

#### Signature

After reasonable inquiry and to the best of the undersigned's knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated: April 1, 2015

#### AMGEN INC.

By:	/s/ David J. Scott
Name:	David J. Scott
Title:	Senior Vice President, General Counsel and
	Secretary

#### AMGEN INVESTMENTS LTD.

By: /s/ David J. Scott

Name: David J. Scott

Title: Senior Vice President and Assistant Secretary

No. Description

1 Joint Filing Agreement

# Joint Filing Agreement

The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the common stock of the Issuer shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G.

Dated: April 1, 2015

#### AMGEN INC.

By:	/s/ David J. Scott
Name:	David J. Scott
Title:	Senior Vice President, General Counsel and
	Secretary

# AMGEN INVESTMENTS LTD.

By:	/s/ David J. Scott
Name:	David J. Scott
Title:	Senior Vice President and Assistant Secretary